{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T18:20:38Z","timestamp":1778091638805,"version":"3.51.4"},"reference-count":54,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,6]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Imatinib, dasatinib, and nilotinib are tyrosine kinase inhibitors (TKIs) used as first-line treatment of chronic myeloid leukemia. Therapeutic drug monitoring is important to achieve treatment efficacy in the case of imatinib and nilotinib, and to control toxicity in the case of dasatinib. New high-sensitivity methods to monitor those drugs are needed, especially for dasatinib. Thus, a simple method to determine plasma levels of imatinib, dasatinib, and nilotinib for application in clinical practice was developed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>TKIs were eluted with a Poroshell 120 EC-C18 column (2.1 \u00d7 75 mm, 2.7 \u03bcm) at 0.5 mL\/min and 60\u00b0C, under gradient conditions through a mobile phase consisting of 4 mmol\/L ammonium formate, pH 3.2 (65%), and acetonitrile (35%). TKIs were detected and quantified by liquid chromatography in tandem with mass spectrometry (LC\/MS\u2013MS) with positive electrospray ionization and analytes were extracted using solid phase extraction (Versaplate-SCX). Internal standards were isotope-labeled for each analyte.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>The method was linear in the range of 2.5\u20135000 ng\/mL for imatinib, 0.75\u2013400 ng\/mL for dasatinib, and 2\u20134000 ng\/mL for nilotinib. The validation assays for accuracy and precision, matrix effect, extraction recovery, carryover, and stability of the samples for all the TKIs were appropriate according to regulatory agencies. Furthermore, imatinib plasma samples, stored for 4 years at \u221280\u00b0C were quite stable in approximately half of the samples.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>The method enables rapid quantification of TKI concentrations and is being applied to therapeutic drug monitoring to adjust dose and to manage adverse reactions in clinical practice.<\/jats:p><\/jats:sec>","DOI":"10.1097\/ftd.0000000000000406","type":"journal-article","created":{"date-parts":[[2017,4,25]],"date-time":"2017-04-25T16:12:35Z","timestamp":1493136755000},"page":"252-262","source":"Crossref","is-referenced-by-count":20,"title":["Simultaneous Determination of Imatinib, Dasatinib, and Nilotinib by Liquid Chromatography-Tandem Mass Spectrometry and Its Application to Therapeutic Drug Monitoring"],"prefix":"10.1097","volume":"39","author":[{"given":"Aneta","family":"Wojnicz","sequence":"first","affiliation":[{"name":"Instituto-Fundaci\u00f3n Te\u00f3filo Hernando, Universidad Aut\u00f3noma de Madrid, Madrid, Spain;"},{"name":"Departamento de Farmacolog\u00eda y Terap\u00e9utica, Facultad de Medicina, Universidad Aut\u00f3noma de Madrid, Madrid, Spain;"},{"name":"Servicio de Farmacolog\u00eda Cl\u00ednica, Instituto de Investigaci\u00f3n Sanitaria, Hospital Universitario de la Princesa, Universidad Aut\u00f3noma de Madrid, Madrid, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"Colom-Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Servicio de Inmunolog\u00eda, Instituto de Investigaci\u00f3n Sanitaria, Hospital Universitario de la Princesa, Universidad Aut\u00f3noma de Madrid, Madrid, Spain; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan L.","family":"Steegmann","sequence":"additional","affiliation":[{"name":"Servicio de Hematolog\u00eda, Instituto de Investigaci\u00f3n Sanitaria, Hospital Universitario de la Princesa, Universidad Aut\u00f3noma de Madrid, Madrid, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia","family":"Mu\u00f1oz-Calleja","sequence":"additional","affiliation":[{"name":"Servicio de Inmunolog\u00eda, Instituto de Investigaci\u00f3n Sanitaria, Hospital Universitario de la Princesa, Universidad Aut\u00f3noma de Madrid, Madrid, Spain; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Abad-Santos","sequence":"additional","affiliation":[{"name":"Instituto-Fundaci\u00f3n Te\u00f3filo Hernando, Universidad Aut\u00f3noma de Madrid, Madrid, Spain;"},{"name":"Departamento de Farmacolog\u00eda y Terap\u00e9utica, Facultad de Medicina, Universidad Aut\u00f3noma de Madrid, Madrid, Spain;"},{"name":"Servicio de Farmacolog\u00eda Cl\u00ednica, Instituto de Investigaci\u00f3n Sanitaria, Hospital Universitario de la Princesa, Universidad Aut\u00f3noma de Madrid, Madrid, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Ruiz-Nu\u00f1o","sequence":"additional","affiliation":[{"name":"Instituto-Fundaci\u00f3n Te\u00f3filo Hernando, Universidad Aut\u00f3noma de Madrid, Madrid, Spain;"},{"name":"Servicio de Farmacolog\u00eda Cl\u00ednica, Instituto de Investigaci\u00f3n Sanitaria, Hospital Universitario de la Princesa, Universidad Aut\u00f3noma de Madrid, Madrid, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230928","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J Clin Oncol."},{"key":"R2-20230928","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med."},{"key":"R3-20230928","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1056\/NEJMe030009","article-title":"Imatinib mesylate-the new gold standard for treatment of chronic myeloid leukemia","volume":"348","author":"Peggs","year":"2003","journal-title":"N Engl J Med."},{"key":"R4-20230928","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med."},{"key":"R5-20230928","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med."},{"key":"R6-20230928","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta16420","article-title":"Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses","volume":"16","author":"Pavey","year":"2012","journal-title":"Health Technol Assess."},{"key":"R7-20230928","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.critrevonc.2012.03.005","article-title":"The expanding options for front-line treatment in patients with newly diagnosed CML","volume":"84","author":"Pinilla-Ibarz","year":"2012","journal-title":"Crit Rev Oncol Hematol."},{"key":"R8-20230928","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.leukres.2010.07.014","article-title":"Relationship of serum imatinib trough level and response in CML patients: long term follow-up","volume":"34","author":"Awidi","year":"2010","journal-title":"Leuk Res."},{"key":"R9-20230928","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/leu.2009.88","article-title":"Pharmacokinetic\/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia","volume":"23","author":"Cortes","year":"2009","journal-title":"Leukemia"},{"key":"R10-20230928","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"key":"R11-20230928","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"key":"R12-20230928","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s00228-011-1200-7","article-title":"Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase","volume":"68","author":"Larson","year":"2012","journal-title":"Eur J Clin Pharmacol."},{"key":"R13-20230928","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00228-012-1385-4","article-title":"Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia","volume":"69","author":"Giles","year":"2013","journal-title":"Eur J Clin Pharmacol."},{"key":"R14-20230928","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2133\/dmpk.DMPK-14-RG-031","article-title":"Influence of UGT1A1 6, 27, and 28 polymorphisms on nilotinib-induced hyperbilirubinemia in Japanese patients with chronic myeloid leukemia","volume":"29","author":"Abumiya","year":"2014","journal-title":"Drug Metab Pharmacokinet."},{"key":"R15-20230928","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.dmpk.2015.09.002","article-title":"Routine therapeutic drug monitoring of tyrosine kinase inhibitors by HPLC-UV or LC-MS\/MS methods","volume":"31","author":"Miura","year":"2016","journal-title":"Drug Metab Pharmacokinet."},{"key":"R16-20230928","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/cncr.24734","article-title":"Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion","volume":"116","author":"Porkka","year":"2010","journal-title":"Cancer"},{"key":"R17-20230928","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s40262-014-0137-2","article-title":"Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets","volume":"53","author":"Yu","year":"2014","journal-title":"Clin Pharmacokinet."},{"key":"R18-20230928","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1248\/bpb.b15-00103","article-title":"Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia","volume":"38","author":"Miura","year":"2015","journal-title":"Biol Pharm Bull."},{"key":"R19-20230928","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/bmc.2796","article-title":"Simple methodology for the therapeutic drug monitoring of the tyrosine kinase inhibitors dasatinib and imatinib","volume":"27","author":"Birch","year":"2013","journal-title":"Biomed Chromatogr."},{"key":"R20-20230928","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.leukres.2009.11.009","article-title":"Simultaneous determination of nilotinib, imatinib and its main metabolite (CGP-74588) in human plasma by ultra-violet high performance liquid chromatography","volume":"34","author":"Davies","year":"2010","journal-title":"Leuk Res."},{"key":"R21-20230928","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1016\/j.talanta.2011.07.093","article-title":"Optimization of the simultaneous determination of imatinib and its major metabolite, CGP74588, in human plasma by a rapid HPLC method using D-optimal experimental design","volume":"85","author":"Golabchifar","year":"2011","journal-title":"Talanta"},{"key":"R22-20230928","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/bmc.1364","article-title":"High-performance liquid chromatography with solid-phase extraction for the quantitative determination of nilotinib in human plasma","volume":"24","author":"Miura","year":"2010","journal-title":"Biomed Chromatogr."},{"key":"R23-20230928","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/chromsci\/49.5.412","article-title":"Quantitative determination of imatinib in human plasma with high-performance liquid chromatography and ultraviolet detection","volume":"49","author":"Miura","year":"2011","journal-title":"J Chromatogr Sci."},{"key":"R24-20230928","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/chrsci\/49.10.753","article-title":"A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients","volume":"49","author":"Pirro","year":"2011","journal-title":"J Chromatogr Sci."},{"key":"R25-20230928","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.cca.2009.10.007","article-title":"Imatinib assay by HPLC with photodiode-array UV detection in plasma from patients with chronic myeloid leukemia: comparison with LC-MS\/MS","volume":"411","author":"Roth","year":"2010","journal-title":"Clin Chim Acta."},{"key":"R26-20230928","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jchromb.2003.10.025","article-title":"Liquid chromatographic method for detection and quantitation of STI-571 and its main metabolite N-desmethyl-STI in plasma, urine, cerebrospinal fluid, culture medium and cell preparations","volume":"799","author":"Schleyer","year":"2004","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R27-20230928","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1016\/j.jchromb.2011.09.048","article-title":"Method development and validation for the simultaneous determination of imatinib mesylate and N-desmethyl imatinib using rapid resolution high performance liquid chromatography coupled with UV-detection","volume":"879","author":"Tan","year":"2011","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R28-20230928","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jchromb.2004.01.032","article-title":"Development and validation of a simple liquid chromatographic method with ultraviolet detection for the determination of imatinib in biological samples","volume":"804","author":"Velpandian","year":"2004","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R29-20230928","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1248\/bpb.34.1126","article-title":"High-performance liquid chromatographic assay for the determination of nilotinib in human plasma","volume":"34","author":"Yuki","year":"2011","journal-title":"Biol Pharm Bull."},{"key":"R30-20230928","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/j.jchromb.2009.05.034","article-title":"A high-performance liquid chromatography-mass spectrometry assay for quantitation of the tyrosine kinase inhibitor nilotinib in human plasma and serum","volume":"877","author":"Parise","year":"2009","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R31-20230928","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1570-0232(03)00206-X","article-title":"Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma","volume":"791","author":"Parise","year":"2003","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R32-20230928","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jchromb.2013.01.037","article-title":"Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC\/MS\/MS","volume":"926","author":"Andriamanana","year":"2013","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R33-20230928","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1007\/s00216-012-5970-2","article-title":"An automated method for the measurement of a range of tyrosine kinase inhibitors in human plasma or serum using turbulent flow liquid chromatography-tandem mass spectrometry","volume":"403","author":"Couchman","year":"2012","journal-title":"Anal Bioanal Chem."},{"key":"R34-20230928","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/j.jchromb.2009.04.028","article-title":"New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma","volume":"877","author":"De Francia","year":"2009","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R35-20230928","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jpba.2011.09.008","article-title":"A validated LC-MS\/MS assay for the simultaneous determination of the anti-leukemic agent dasatinib and two pharmacologically active metabolites in human plasma: application to a clinical pharmacokinetic study","volume":"58","author":"Furlong","year":"2012","journal-title":"J Pharm Biomed Anal."},{"key":"R36-20230928","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cca.2011.09.012","article-title":"Development and clinical application of a LC-MS\/MS method for simultaneous determination of various tyrosine kinase inhibitors in human plasma","volume":"413","author":"Gotze","year":"2012","journal-title":"Clin Chim Acta."},{"key":"R37-20230928","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jchromb.2009.04.045","article-title":"Therapeutic drug monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry","volume":"877","author":"Haouala","year":"2009","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R38-20230928","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/bmc.2814","article-title":"Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry","volume":"27","author":"Lankheet","year":"2013","journal-title":"Biomed Chromatogr."},{"key":"R39-20230928","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/bmc.2819","article-title":"Imatinib assay by high-performance liquid chromatography in tandem mass spectrometry with solid-phase extraction in human plasma","volume":"27","author":"Moreno","year":"2013","journal-title":"Biomed Chromatogr."},{"key":"R40-20230928","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1016\/j.jchromb.2009.10.008","article-title":"Development of a high-performance liquid chromatographic-mass spectrometric method for the determination of cellular levels of the tyrosine kinase inhibitors lapatinib and dasatinib","volume":"877","author":"Roche","year":"2009","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R41-20230928","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jchromb.2013.08.013","article-title":"A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry","volume":"937","author":"van Erp","year":"2013","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R42-20230928","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1093\/chromsci\/bmt037","article-title":"LC-MS-MS determination of imatinib and N-desmethyl imatinib in human plasma","volume":"52","author":"Zhang","year":"2014","journal-title":"J Chromatogr Sci."},{"key":"R43-20230928","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cca.2011.02.023","article-title":"Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC\/MS-MS","volume":"412","author":"Bouchet","year":"2011","journal-title":"Clin Chim Acta."},{"key":"R44-20230928","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jchromb.2012.07.011","article-title":"Simultaneous measurement of imatinib, nilotinib and dasatinib in dried blood spot by ultra high performance liquid chromatography tandem mass spectrometry","volume":"903","author":"Kralj","year":"2012","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R47-20230928","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/FTD.0000000000000309","article-title":"Ultrafast online SPE-MS\/MS method for quantification of 3 tyrosine kinase inhibitors in human plasma","volume":"38","author":"Vrobel","year":"2016","journal-title":"Ther Drug Monit."},{"key":"R48-20230928","first-page":"85","article-title":"Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a phase III study","volume":"5","author":"Wang","year":"2013","journal-title":"Clin Pharmacol."},{"key":"R49-20230928","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jchromb.2005.11.009","article-title":"Standard line slopes as a measure of a relative matrix effect in quantitative HPLC-MS bioanalysis","volume":"830","author":"Matuszewski","year":"2006","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R50-20230928","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/S1044-0305(00)00163-X","article-title":"Mechanistic investigation of ionization suppression in electrospray ionization","volume":"11","author":"King","year":"2000","journal-title":"J Am Soc Mass Spectrom."},{"key":"R51-20230928","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jpba.2004.10.035","article-title":"Minimization of ion suppression in LC-MS\/MS analysis through the application of strong cation exchange solid-phase extraction (SCX-SPE)","volume":"37","author":"Shen","year":"2005","journal-title":"J Pharm Biomed Anal."},{"key":"R52-20230928","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3324\/haematol.2011.045666","article-title":"Plasma exposure of imatinib and its correlation with clinical response in the tyrosine kinase inhibitor optimization and selectivity trial","volume":"97","author":"Guilhot","year":"2012","journal-title":"Haematologica"},{"key":"R53-20230928","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ccr.2008.11.001","article-title":"Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis","volume":"14","author":"Shah","year":"2008","journal-title":"Cancer Cell"},{"key":"R54-20230928","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1756-8722-5-23","article-title":"Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation","volume":"5","author":"Takahashi","year":"2012","journal-title":"J Hematol Oncol."},{"key":"R55-20230928","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"R56-20230928","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1182\/blood-2014-06-578617","article-title":"Molecular response in CML: where is the bar?","volume":"124","author":"Baccarani","year":"2014","journal-title":"Blood"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201706000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T19:26:33Z","timestamp":1719170793000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201706000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000406","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]}}}